INTRODUCTION AND OBJECTIVES: Partial nephrectomy has become the gold standard for localized renal masses as it provides excellent oncologic control while preserving renal mass and global renal function. However, it remains controversial if partial nephrectomy improves mortality, renal-related events and cardiovascular disease. The objective of this study is to assess the impact of comorbidity on longterm outcomes.
METHODS: Comorbidity was estimated using the Johns Hopkins Adjusted Clinical Group (ACG) system which provided Aggregated Diagnostic Groups (ADG) scores. This score was determined based on resource use, procedures, and diagnoses in the year prior to nephrectomy, with a higher score indicative of greater expected resource utilization. The primary outcome was all-cause mortality, with two prespecified comorbid groups: ADG <7.5 or >7.5. Secondary outcomes included major cardiovascular events and non-cancer mortality.
RESULTS: Between 2002-2010, we identified 575 partial and 882 radical nephrectomies for tumors measuring 7cm or less at 3 academic centers. The mean (standard deviation) 1-year post-operative eGFR was 71 (22) mL/min/1.73 m2 and 52 (13) mL/min/1.73 m2 in the partial nephrectomy and radical nephrectomy group, respectively. Mortality rates were highest in the ADG >7.5 group with 2.9 vs 1.5 per 100 person years in the partial nephrectomy group and 4.9 vs 3.4 per 100 person years in the radical nephrectomy group. However, there was no evidence that ADG comorbidity stratification modified long term outcomes between the partial and radical nephrectomy groups. All-cause mortality HRs are as follows: ADG <7.5 HR 1.62, 95% CI (1.04-2.52) versus ADG >7.5 HR 1.29, 95% CI (0.87-1.89) with an interaction p-value that was not significant (p[0.46). This trend continued for non-cancer mortality and cardiovascular death.
CONCLUSIONS: The absolute death rate was nearly doubled in the higher comorbid group (ADG >7.5) indicating ADG scoring properly risk stratify these patients. However, comorbidity risk stratification did not modify long-term outcomes between the partial nephrectomy versus radical nephrectomy group in all-cause mortality, non-cancer mortality and cardiovascular death. 4 cm) is currently not the standard of care; instead, most urologists proceed with extirpative therapy despite the knowledge that 20% of these masses are benign. For all other solid, organ-confined masses (e.g. prostate, bladder, lung, breast, etc.), the standard of care mandates a biopsy-established diagnosis prior to treatment. In order to discern why the kidney is an outlier for pre-treatment biopsy, we sought to compare the efficacy and safety of renal mass biopsy to biopsy of a mass in other major solid organ systems.
METHODS: We reviewed meta-analyses, systematic reviews, and clinical studies with regard to biopsy of a mass in the following organs: prostate, lung, breast, thyroid, pancreas, and kidney. Rigorous study designs that minimized bias and systematic error were identified; only reports dealing exclusively with needle biopsy were included.
RESULTS: Organ-specific mass biopsy data regarding sensitivity, specificity, diagnostic accuracy, and complication rate were extracted from 10 studies comprising 17,830 breast, 10,383 lung, 4,766 pancreas, 4,746 thyroid, 6 ,959 prostate, and 2,867 renal masses. The sensitivity and specificity for biopsy of a small renal mass were 99% and 98%, respectively, while the sensitivity and specificity for needle biopsy in the other organs ranged from 48% -99% and 96% -100%, respectively (Table 1 ). The complication rate for renal mass biopsy was 8% (less than 1% of these were Clavien grade !2), and the diagnostic accuracy (i.e. concordance with surgical pathology) of small renal mass biopsy was 96%, both of which compared favorably to or exceeded biopsy results in the other solid organs.
CONCLUSIONS: The safety and efficacy for needle biopsy of a small renal mass provides results equivalent to or better than biopsy of a solid mass in other organ systems. In light of the well-known 20% incidence of a benign diagnosis at the time of small renal mass exploration, the absence of routine preoperative needle biopsy remains an inexplicable urological conundrum. 
